FR20C1003I2 - Compose de carboxamide heterocyclique diamino - Google Patents

Compose de carboxamide heterocyclique diamino

Info

Publication number
FR20C1003I2
FR20C1003I2 FR20C1003C FR20C1003C FR20C1003I2 FR 20C1003 I2 FR20C1003 I2 FR 20C1003I2 FR 20C1003 C FR20C1003 C FR 20C1003C FR 20C1003 C FR20C1003 C FR 20C1003C FR 20C1003 I2 FR20C1003 I2 FR 20C1003I2
Authority
FR
France
Prior art keywords
carboxamide compound
heterocyclic carboxamide
diamino heterocyclic
diamino
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1003C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kotobuki Seiyaku Co Ltd
Astellas Pharma Inc
Original Assignee
Kotobuki Seiyaku Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1003(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kotobuki Seiyaku Co Ltd, Astellas Pharma Inc filed Critical Kotobuki Seiyaku Co Ltd
Publication of FR20C1003I1 publication Critical patent/FR20C1003I1/fr
Application granted granted Critical
Publication of FR20C1003I2 publication Critical patent/FR20C1003I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
FR20C1003C 2009-05-08 2020-02-04 Compose de carboxamide heterocyclique diamino Active FR20C1003I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009113936 2009-05-08
PCT/JP2010/057751 WO2010128659A1 (fr) 2009-05-08 2010-05-06 Composé de carboxamide hétérocyclique diamino

Publications (2)

Publication Number Publication Date
FR20C1003I1 FR20C1003I1 (fr) 2020-03-20
FR20C1003I2 true FR20C1003I2 (fr) 2020-12-04

Family

ID=43050157

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1003C Active FR20C1003I2 (fr) 2009-05-08 2020-02-04 Compose de carboxamide heterocyclique diamino

Country Status (29)

Country Link
US (2) US8969336B2 (fr)
EP (2) EP3009428B1 (fr)
JP (1) JP5364159B2 (fr)
KR (1) KR101614572B1 (fr)
CN (1) CN102421761B (fr)
AU (1) AU2010245545B2 (fr)
BR (1) BRPI1011838B8 (fr)
CA (1) CA2760061C (fr)
CY (3) CY1117546T1 (fr)
DK (2) DK2428508T3 (fr)
ES (2) ES2559230T3 (fr)
FR (1) FR20C1003I2 (fr)
HK (1) HK1219105A1 (fr)
HR (2) HRP20151435T8 (fr)
HU (3) HUE038515T2 (fr)
IL (1) IL216132A (fr)
LT (2) LT3009428T (fr)
LU (1) LUC00147I2 (fr)
MX (1) MX2011011875A (fr)
NL (1) NL301028I2 (fr)
NO (2) NO3009428T3 (fr)
PL (2) PL2428508T3 (fr)
PT (2) PT2428508E (fr)
RS (2) RS57045B1 (fr)
SI (2) SI3009428T1 (fr)
SM (1) SMT201600075B (fr)
TW (1) TWI484961B (fr)
WO (1) WO2010128659A1 (fr)
ZA (1) ZA201108642B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
ES2546502T3 (es) 2008-04-16 2015-09-24 Portola Pharmaceuticals, Inc. 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101852169B1 (ko) 2010-05-20 2018-04-26 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
WO2012061303A1 (fr) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétéroaryle et leurs utilisations
WO2012061299A1 (fr) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétérocycliques et leurs utilisations
WO2012061415A1 (fr) * 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Oxypyrimidines en tant que modulateurs de syk
EP2637502B1 (fr) 2010-11-10 2018-01-10 Celgene CAR LLC Inhibiteurs d'egfr sélectifs d'un mutant et leurs utilisations
CN102285969B (zh) * 2011-06-28 2013-06-19 山东大学 N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用
DK2748192T3 (en) 2011-08-23 2019-02-25 Found Medicine Inc KIF5B-RET-FUSION MOLECULES AND APPLICATIONS THEREOF
CA2853498A1 (fr) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methodes de traitement d'une maladie ou d'une affection associee a la tyrosine-kinase btk (bruton's tyrosine kinase)
MX363551B (es) * 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
UA111010C2 (uk) * 2012-01-17 2016-03-10 Астеллас Фарма Інк. Сполука піразинкарбоксаміду
CN104284584B (zh) 2012-03-15 2019-06-04 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的盐
SG11201405691WA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
CA2890006C (fr) * 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Inhibiteurs de kinase alk
WO2014100748A1 (fr) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Composés hétéroarylés et leurs utilisations
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015039613A1 (fr) * 2013-09-18 2015-03-26 北京韩美药品有限公司 Composé inhibant les activités kinase de btk et/ou jak3
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2015061247A2 (fr) * 2013-10-21 2015-04-30 Merck Patent Gmbh Composés hétéroaryle servant d'inhibiteurs de la btk et leurs utilisations
EP3077388A1 (fr) * 2013-12-05 2016-10-12 Pharmacyclics, LLC Inhibiteurs de la tyrosine kinase de bruton
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CA2938818C (fr) * 2014-02-04 2023-03-07 Astellas Pharma Inc. Composition pharmaceutique comprenant un compose carboxamide heterocyclique diamine en tant que principe actif
CN104016977B (zh) * 2014-06-13 2016-06-22 山东大学 一种取代噻二嗪二酮类衍生物及其制备方法与应用
EP3179858B1 (fr) 2014-08-13 2019-05-15 Celgene Car Llc Formes et compositions d'un inhibiteur d'erk
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
US9796685B2 (en) 2014-12-16 2017-10-24 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
PL3318259T3 (pl) 2015-07-03 2023-05-02 Astellas Pharma Inc. Stabilna kompozycja farmaceutyczna do podawania doustnego
SI3322706T1 (sl) 2015-07-16 2021-04-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
WO2017019487A1 (fr) 2015-07-24 2017-02-02 Celgene Corporation Procédés de synthèse de chlorhydrate de (1r,2r,5r)-5-amino-2-méthylcyclohexanol et intermédiaires utiles à cet effet
WO2017078049A1 (fr) * 2015-11-04 2017-05-11 アステラス製薬株式会社 Composition pharmaceutique pour l'immunothérapie anticancéreuse et/ou pour l'immunostimulation, contenant comme principe actif un composé diamino carboxamide hétérocyclique
WO2017146236A1 (fr) 2016-02-26 2017-08-31 小野薬品工業株式会社 Médicament pour le traitement du cancer caractérisé par l'administration d'une association d'un inhibiteur de l'axl et d'un inhibiteur de point de contrôle immunitaire
CN106083821B (zh) * 2016-06-22 2019-01-11 上海皓元生物医药科技有限公司 一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
KR20200013683A (ko) 2017-05-17 2020-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 오피오이드에 의한 통증 치료 개선용 ｆｌｔ3 저해제
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
EP3695839A4 (fr) 2017-10-13 2021-07-14 ONO Pharmaceutical Co., Ltd. Agent thérapeutique pour cancers solides, qui contient un inhibiteur d'axl en tant que principe actif
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
WO2019143994A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
US11512074B2 (en) 2018-03-28 2022-11-29 Shenzhen Targetrx, Inc. Substituted diamino heterocyclic carboxamide compound and a composition containing the compound and use thereof
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
CN112839930B (zh) * 2018-09-30 2022-03-15 南京明德新药研发有限公司 作为flt3和axl抑制剂的3,9-二氮杂螺[5,5]十一烷类化合物
SG11202104017VA (en) 2018-10-22 2021-05-28 Esker Therapeutics Inc Tyk2 inhibitors and uses thereof
JP7455810B2 (ja) 2019-03-13 2024-03-26 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法
WO2020204142A1 (fr) 2019-04-03 2020-10-08 アステラス製薬株式会社 Composition médicinale
WO2021197344A1 (fr) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 Forme cristalline d'un composé de diazaspiropyrane
CN111423387B (zh) * 2020-05-11 2022-03-08 苏州康纯医药科技有限公司 一种Gilteritinib关键中间体的制备方法
AU2021284676A1 (en) * 2020-06-01 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. New pyrazine compound
WO2022009235A1 (fr) * 2020-07-10 2022-01-13 Msn Laboratories Private Limited, R&D Center Procédé de préparation de fumarate de giltéritinib
CN113943288A (zh) * 2020-07-17 2022-01-18 微境生物医药科技(上海)有限公司 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN112225703B (zh) * 2020-09-28 2022-03-11 广州智睿医药科技有限公司 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物
CN117355508A (zh) * 2020-10-12 2024-01-05 西藏海思科制药有限公司 一种杂环衍生物及其在医药上的应用
WO2023027966A1 (fr) * 2021-08-24 2023-03-02 Biomea Fusion, Inc. Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023178094A2 (fr) * 2022-03-14 2023-09-21 Purdue Research Foundation Inhibiteur de tyrosine kinase de la rate, composition et procédés d'utilisation
WO2023225005A1 (fr) * 2022-05-17 2023-11-23 Biomea Fusion, Inc. Polythérapie à base de flt3 pour le cancer et compositions associées
CN115124590A (zh) * 2022-07-05 2022-09-30 武汉大学中南医院 一种靶向降解flt3-itd突变蛋白的protac类化合物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5107900A (en) 1999-06-09 2000-12-28 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
JP4529685B2 (ja) 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2008013499A (ja) 2006-07-06 2008-01-24 Sankyo Co Ltd ５−シアノニコチンアミド誘導体
WO2008016660A2 (fr) * 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Composés de traitement de la leucémie
US20080070930A1 (en) 2006-08-24 2008-03-20 Huang Kenneth H Pyrimidine and Pyrazine Derivatives
EP1914240B1 (fr) 2006-10-11 2009-12-02 Astellas Pharma Inc. Gène de fusion EML4-ALK
EP2222647B1 (fr) 2006-10-23 2015-08-05 Cephalon, Inc. Dérives bicycliques fusionnes de 2,4-diaminopyrimidine utilises comme inhibiteurs de alk et c-met
CN103641833A (zh) 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CA2673184A1 (fr) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh Nouveaux composes
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
EP2188292B1 (fr) 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited Dérivés de 2-[(2-{phénylamino}-1h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzamide en tant qu'inhibiteur d'igf-1r pour le traitement du cancer
WO2009032694A1 (fr) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse
US8426417B2 (en) 2007-09-28 2013-04-23 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
US20090270418A1 (en) 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
JP5298187B2 (ja) 2008-04-07 2013-09-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CN102056925A (zh) 2008-04-07 2011-05-11 Irm责任有限公司 作为激酶抑制剂的化合物和组合物
CA2723205C (fr) * 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides comme inhibiteurs d'activite de syk ou de jak kinase
KR20170051521A (ko) * 2008-04-16 2017-05-11 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.

Also Published As

Publication number Publication date
EP3009428A1 (fr) 2016-04-20
LT3009428T (lt) 2018-04-10
HRP20151435T8 (hr) 2016-07-01
DK3009428T3 (en) 2018-03-26
IL216132A (en) 2015-10-29
NL301028I1 (nl) 2020-01-22
PT3009428T (pt) 2018-04-02
RU2526253C2 (ru) 2014-08-20
SI3009428T1 (en) 2018-04-30
JP5364159B2 (ja) 2013-12-11
RU2011149799A (ru) 2013-06-20
NO3009428T3 (fr) 2018-07-21
MX2011011875A (es) 2011-12-08
TW201105326A (en) 2011-02-16
PT2428508E (pt) 2016-02-29
BRPI1011838B8 (pt) 2021-05-25
CY2020004I1 (el) 2020-05-29
CN102421761A (zh) 2012-04-18
JPWO2010128659A1 (ja) 2012-11-01
NO2020001I1 (no) 2020-01-16
PL2428508T3 (pl) 2016-05-31
LTPA2020002I1 (lt) 2020-02-10
HUE038515T2 (hu) 2018-10-29
US20120040968A1 (en) 2012-02-16
TWI484961B (zh) 2015-05-21
BRPI1011838B1 (pt) 2021-03-16
ES2667706T3 (es) 2018-05-14
US8969336B2 (en) 2015-03-03
FR20C1003I1 (fr) 2020-03-20
CY1120367T1 (el) 2019-07-10
SI2428508T1 (sl) 2016-04-29
HRP20151435T1 (hr) 2016-03-25
KR101614572B1 (ko) 2016-04-21
HRP20180368T1 (hr) 2018-04-06
RS57045B1 (sr) 2018-05-31
ZA201108642B (en) 2013-02-27
HUE026647T2 (en) 2016-07-28
DK2428508T3 (en) 2016-02-01
HK1219105A1 (zh) 2017-03-24
BRPI1011838A2 (pt) 2018-02-06
RS54552B1 (en) 2016-06-30
HUS2000005I1 (hu) 2020-03-30
EP2428508B9 (fr) 2016-04-20
US20140371196A1 (en) 2014-12-18
EP3009428B1 (fr) 2018-02-21
CA2760061A1 (fr) 2010-11-11
CA2760061C (fr) 2017-02-28
AU2010245545A1 (en) 2011-11-03
SMT201600075B (it) 2016-04-29
LUC00147I1 (fr) 2020-02-10
KR20120007523A (ko) 2012-01-20
EP2428508A1 (fr) 2012-03-14
EP2428508A4 (fr) 2012-11-28
AU2010245545B2 (en) 2014-09-11
LUC00147I2 (fr) 2021-02-12
PL3009428T3 (pl) 2018-07-31
CY2020004I2 (el) 2020-05-29
WO2010128659A1 (fr) 2010-11-11
HUS000511I2 (hu) 2021-03-29
NL301028I2 (nl) 2020-04-15
IL216132A0 (en) 2012-01-31
ES2559230T3 (es) 2016-02-11
CN102421761B (zh) 2014-06-18
LTC2428508I2 (lt) 2020-12-28
EP2428508B1 (fr) 2015-12-16
US9487491B2 (en) 2016-11-08
CY1117546T1 (el) 2017-04-26

Similar Documents

Publication Publication Date Title
FR20C1003I2 (fr) Compose de carboxamide heterocyclique diamino
CY2021001I2 (el) Παραγωγα ετεροκυκλικου αμιδιου χρησιμα ως μικροβιοκτονα
BRPI0918045A2 (pt) compostos de carboxamida heterocíclicos
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
DK2540728T3 (da) Heterocyklisk forbindelse
ECSP12011999A (es) Derivados benzamida sustituidos
BR112012005616A2 (pt) compostos antivirais heterocíclicos
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI0906705A2 (pt) Composto heterocíclicos
BRPI1010852A2 (pt) compostos antivirais heterocíclicos
DK2397480T3 (da) Diazepindionderivat
BRPI1009287A2 (pt) composto de quinoxalina
BR112012010519A2 (pt) derivados de sulfonamida heterocíclicos
BRPI1016266A2 (pt) compostos antivirais heterocíclicos
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI1013493A2 (pt) composto de pirimidina
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
FR2935592B1 (fr) Poudrier
BR112012005960A2 (pt) n-fenil-1-(4-piridinil)-1h-pirazol-3-aminas substituídas
DK2387580T3 (da) Deoxyactagardinderivater
BRPI1011416A2 (pt) derivados de antraquinova novos
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
FR2947556B1 (fr) Composition polyamide modifiee
CU23884B1 (es) Derivados de dibenzotiazepina